This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Gaps in Mycosis Fungoides-Cutaneous T-Cell Lymphoma: Early Detection, Diagnosis, and Treatment

Gaps in Mycosis Fungoides-Cutaneous T-Cell Lymphoma: Early Detection, Diagnosis, and Treatment



Time to Complete

1 hour


March 5, 2018


March 5, 2019
Add to Queue

Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider

Provided by Integrity Continuing Education, Inc.

Commercial Supporter

Supported by an educational grant from Actelion Pharmaceuticals US, Inc.

Program Description

Mycosis fungoides (MF) is a rare, cutaneous T-cell lymphoma (MF-CTCL) which presents life-long management challenges. Although the prognosis for advanced disease is poor, for the majority of patients who present with early-stage disease, a number of efficacious treatment options are available. However, early-stage MF-CTCL still provides a significant challenge for clinicians. Due to the rare nature of this disease, clinicians are often not familiar with the presentation of MF-CTCL and an accurate diagnosis is frequently delayed, as early-stage MF-CTCL mimics a number of common cutaneous diseases.

Intended Audience

This educational initiative has been designed for dermatologists, dermatology oncologists, oncologists, dermatology nurses, advanced practitioners, pharmacists, and healthcare providers caring for patients with or suspected to have early-stage MF-CTCL.

Educational Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe signs and symptoms that should prompt suspicion of mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL)
  • Identify barriers to the accurate diagnosis of MF-CTCL and explain how such barriers may be effectively addressed
  • Outline an individualized approach to the treatment of early-stage MF-CTCL that includes appropriate use of skin-directed therapies for optimized patient care

Conflict Of Interest Disclosure Policy

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Integrity Continuing Education is committed to providing learners with high-quality CME/CE activities and related materials that promote improvement or quality in healthcare and not a specific proprietary business interest or a commercial interest.

The following faculty/planners reported their financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:


Larisa Geskin, MD, FAAD
Associate Professor of Dermatology and Medicine
Comprehensive Cutaneous Oncology Center
Columbia University
New York, NY

Dr. Geskin discloses the following:
Consultant: Actelion, Bristol-Myers Squibb, Eisai, Innate, Kyowa, Medivir, Therakos
Speaker’s Bureaus: Actelion, Therakos
Research: Actelion, Bristol-Myers Squibb

Accredited Provider Disclosure

Patima Tanapat, PhD, has no real or apparent conflicts of interest to disclose.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

Designation Statement

Integrity Continuing Education designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integrity Continuing Education and Actelion do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education and Actelion. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.


There are no fees for participating and receiving CME credit for this activity. During the period of March 5, 2018 through March 5, 2019, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pre-test
  • Study the educational activity
  • Complete the post-test and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or higher.

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc., at (855) 835-4004 or

If you have any questions relating to your certificate or other issues with this activity, please contact

Privacy Policy


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue